$3.87
-0.13 (-3.25%)
SION News2 articles
Sionna Plunges 91% as CF Drug Fails Trial, Market Cap Drops Below Cash
Sionna shares fell 91% after its CF drug SION-719 failed a Phase 2a trial, with efficacy far below expectations. The stock now trades below cash value.
Sionna Therapeutics Collapses 92% After Phase 2a Setback
Sionna Therapeutics (SION) tumbled 92% after its Phase 2a trial failed to meet the primary endpoint, pushing the market cap below its cash holdings. Vertex (VRTX) rose on reduced competitive risk.